Amgen DeLLphi309 Recurrent Small Cell Lung Cancer

Purpose of this Study

We are doing this study to find out if an experimental drug called tarlatamab (the study drug) is a safe and effective option for people who have small cell lung cancer (SCLC) that has progressed and spread to other parts of the body.

Who Can Participate?

Eligibility

Adults ages 18+ who:
  • Are diagnosed with SCLC
  • Have received at least one previous line of treatment with a platinum-based regimen
  • Had their disease get worse after treatment
For more information about who can join this study, please contact the study team at annemarie.peters@duke.edu.

Age Range

18-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

Description

If you choose to join this study, you will get a random assignment (by chance) to 1 of 3 groups. Depending on your assignment, you might:
  • Get a dose of the study drug every 2 weeks; OR
  • Get a dose of the study drug every 3 weeks; OR
  • Get a dose of the study drug every 4 weeks
The study drug is given as an intravenous (IV) infusion through a vein. The length of time you receive the study drug will depend on how you respond to it.

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

No

Spanish Materials Available

No

Study Details

Full Title

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with Small Cell Lung Cancer (SCLC)(DeLLphi-309)

Principal Investigator

Jeffrey
Clarke

Protocol Number

PRO00117430

NCT ID

NCT06745323

Phase

II

Enrollment Status

Pending Open to Enrollment
ClinicalTrials.gov